Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors

BACKGROUND: Next-generation cancer immunotherapies are designed to broaden the therapeutic repertoire by targeting new immune checkpoints including lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin and mucin-domain containing-3 (TIM-3). Yet, the molecular and cellular mechanisms by whic...

Descripción completa

Detalles Bibliográficos
Autores principales: Natoli, Marina, Hatje, Klas, Gulati, Pratiksha, Junker, Fabian, Herzig, Petra, Jiang, Zhiwen, Davydov, Iakov I, Germann, Markus, Trüb, Marta, Marbach, Daniel, Zwick, Adrian, Weber, Patrick, Seeber, Stefan, Wiese, Mark, Lardinois, Didier, Heinzelmann-Schwarz, Viola, Rosenberg, Robert, Tietze, Lothar, Mertz, Kirsten D, Umaña, Pablo, Klein, Christian, Codarri-Deak, Laura, Kao, Henry, Zippelius, Alfred
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628669/
https://www.ncbi.nlm.nih.gov/pubmed/36319064
http://dx.doi.org/10.1136/jitc-2022-005548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628669/
https://www.ncbi.nlm.nih.gov/pubmed/36319064
http://dx.doi.org/10.1136/jitc-2022-005548

Ejemplares similares